We aim to solve the age of problems in cancer treatment where less than 1% of drugs can penetrate a tumor target owing to biological barriers such as the blood-brain barrier and the tumor endothelium barrier. This poor drug penetration contributes to a secondary problem where the high doses of drug conventionally used to kill a tumor is so toxic that it is also harming the patient (weight loss, hair loss, vomiting etc). Our solution involves the use of ultrasound triggered microbubbles proven safe for diagnostic imaging which have been optimized to solve cancer drug delivery. Our innovation is the development of monodisperse size-isolated microbubbles (SIMBs), which are proven in preclinical trials to provide unprecedented control in this method that no other microbubble agent can, such as improved drug delivery to the disease site, increasing the window of treatment and homogenous and consistent drug uptake at the disease site. Our technology can delivery nanoparticles, immunotherapies and chemotherapies across biological barriers while reducing or eliminating drug side-effects.